Dean M. Najarian, PharmD, BCPP

  • 2Articles
  • 9.2KReads
  • 1999–2023Active
  • 10Collaborators
  • 4Citations

About

Dean M. Najarian, PharmD, BCPP, is affiliated with Janssen Scientific Affairs, LLC, in Titusville, New Jersey. Najarian has published research focused on neurology and schizophrenia/schizoaffective disorders, including studies on long-acting injectable paliperidone palmitate and the metabolic effects of olanzapine. Contributions span from 1999 to 2023, with frequent collaboration with co-authors such as David N. Osser and H. Lynn Starr.

Publications

JCP
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
Original Research

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

September 25, 2023

Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
, , , et al
JCP
Original Research

Olanzapine Increases Weight and Serum Triglyceride Levels

November 30, 1999

, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe